These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 32860707)

  • 1. Impacts of the Percentage of Basal Core Promoter Mutation on the Progression of Liver Fibrosis After Hepatitis B e Antigen Seroconversion.
    Wu JF; Chang KC; Ni YH; Hsu HY; Chang MH
    J Infect Dis; 2021 Apr; 223(8):1381-1389. PubMed ID: 32860707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion.
    Yang HC; Chen CL; Shen YC; Peng CY; Liu CJ; Tseng TC; Su TH; Chuang WL; Yu ML; Dai CY; Liu CH; Chen PJ; Chen DS; Kao JH
    Hepatology; 2013 Mar; 57(3):934-43. PubMed ID: 23112104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High level of hepatitis B virus DNA after HBeAg-to-anti-HBe seroconversion is related to coexistence of mutations in its precore and basal core promoter.
    Peng XM; Huang GM; Li JG; Huang YS; Mei YY; Gao ZL
    World J Gastroenterol; 2005 May; 11(20):3131-4. PubMed ID: 15918203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative dynamics of hepatitis B basal core promoter and precore mutants before and after HBeAg seroconversion.
    Nie H; Evans AA; London WT; Block TM; Ren XD
    J Hepatol; 2012 Apr; 56(4):795-802. PubMed ID: 22173170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations of pre-core and basal core promoter before and after hepatitis B e antigen seroconversion.
    Kamijo N; Matsumoto A; Umemura T; Shibata S; Ichikawa Y; Kimura T; Komatsu M; Tanaka E
    World J Gastroenterol; 2015 Jan; 21(2):541-8. PubMed ID: 25593470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different precore/core mutations of hepatitis B interact with, limit, or favor liver fibrosis severity.
    Ducancelle A; Pivert A; Bertrais S; Boursier J; Balan V; Veillon P; le Guillou-Guillemette H; Thibault V; Castelain S; Roquebert B; Coste-Burel M; Mackiewicz V; Schvoerer E; Larrat S; Maylin S; Alain S; Loustaud-Ratti V; Gordien E; Gozlan J; Brodard V; Chevaliez S; Calès P; Lunel-Fabiani F
    J Gastroenterol Hepatol; 2016 Oct; 31(10):1750-1756. PubMed ID: 26992056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of hepatitis B e antigen-negative hepatitis in chronic hepatitis B virus-infected patients from childhood to adulthood.
    Wu JF; Chiu YC; Chang KC; Chen HL; Ni YH; Hsu HY; Chang MH
    Hepatology; 2016 Jan; 63(1):74-82. PubMed ID: 26389515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution and Clinical Significance of Hepatitis B virus A1762T/G1764A Double Mutation in Chronic Hepatitis B Patients: A Cross-Sectional Study.
    Changsri K; Duangchanda T; Soimanee T; Fuckpo W; Pipatsatitpong D; Akekawatchai C
    Asian Pac J Cancer Prev; 2024 Feb; 25(2):371-377. PubMed ID: 38415521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low HBeAg serum levels correlate with the presence of the double A1762T/G1764A core promoter mutation and a positive response to interferon in patients with chronic hepatitis B virus infection.
    Marrone A; Zampino R; Luongo G; Utili R; Karayiannis P; Ruggiero G
    Intervirology; 2003; 46(4):222-6. PubMed ID: 12931030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B virus basal core promoter mutations A1762T/G1764A are associated with genotype C and a low serum HBsAg level in chronically-infected HBeAg-positive Chinese patients.
    Yan CH; Zhao CY; Ding H; Peng YQ; Jin PY; Yan L; Zhuang H; Li T
    Antiviral Res; 2012 Nov; 96(2):108-14. PubMed ID: 22960603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of hepatitis B virus A1762T/G1764A double mutant strain in patients in Southern Brazil.
    Silva Souza ACD; Souza Marasca G; Kretzmann-Filho NA; Dall-Bello A; Alexandre Kliemann D; Valle Tovo C; Gorini da Veiga AB
    Braz J Infect Dis; 2017; 21(5):525-529. PubMed ID: 28606415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis.
    Liu S; Zhang H; Gu C; Yin J; He Y; Xie J; Cao G
    J Natl Cancer Inst; 2009 Aug; 101(15):1066-82. PubMed ID: 19574418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next generation sequencing identifies baseline viral mutants associated with treatment response to pegylated interferon in HBeAg-positive chronic hepatitis B.
    Chuaypen N; Payungporn S; Poovorawan K; Chotiyaputta W; Piratvisuth T; Tangkijvanich P
    Virus Genes; 2019 Oct; 55(5):610-618. PubMed ID: 31359359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation Changes in the preC/Core Promoter in HBeAg-Positive Patients With Chronic Hepatitis B During Interferon Therapy.
    Geng Y; Wang X; Lu X; Wu X; Xu N; Han L; Xu J
    Medicine (Baltimore); 2016 Feb; 95(5):e2657. PubMed ID: 26844490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presence of hepatitis B virus core promoter mutations pre-seroconversion predict persistent viral replication after HBeAg loss.
    Ferns RB; Naoumov NV; Gilson RJ; Tedder RS
    J Clin Virol; 2007 Jul; 39(3):199-204. PubMed ID: 17526429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of characteristics of HBV quasispecies with hepatitis B surface antigen seroconversion after pegylated interferon-α-2a treatment in child patients.
    Yang J; Yang G; He H; Ning L; Liu Z; Fu Q; Chen H; Deng H; Wang Z; Luo K
    Antivir Ther; 2018; 23(7):567-574. PubMed ID: 30095435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naturally occurring basal core promoter A1762T/G1764A dual mutations increase the risk of HBV-related hepatocellular carcinoma: a meta-analysis.
    Yang Z; Zhuang L; Lu Y; Xu Q; Tang B; Chen X
    Oncotarget; 2016 Mar; 7(11):12525-36. PubMed ID: 26848866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B.
    Tangkijvanich P; Komolmit P; Mahachai V; Sa-nguanmoo P; Theamboonlers A; Poovorawan Y
    J Clin Virol; 2009 Oct; 46(2):117-23. PubMed ID: 19651540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of hepatitis B virus precore and core promoter variants in Korean patients with chronic hepatitis B.
    Yim SY; Um SH; Young Jung J; Kim TH; Kim JD; Keum B; Seo YS; Yim HJ; Jeen YT; Lee HS; Chun HJ; Kim CD; Ryu HS
    J Clin Gastroenterol; 2015 Jan; 49(1):61-8. PubMed ID: 24406435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B core antibody and liver stiffness measurements predict HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with minimally elevated alanine aminotransferase (ALT) levels.
    Fu X; Lou H; Chen F; Gao X; Lin Z
    Clin Exp Med; 2020 May; 20(2):241-248. PubMed ID: 32052245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.